According to molecular docking results, angelicin could bind freely to the hub targets, and the hub targets BAX, BRIC2, BCL2, and Casp9 may be effective targets by which angelicin affects osteosarcoma cells. The gene discussed is BCL2; the disease is osteosarcoma.